Volume Alert - CTSH 53.62 Cognizant Technology Solutions

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - CTSH 53.62 Cognizant Technology Solutions $CTSH Hit a high today of 53.71 Closing the day 11/07/14 at 53.62 +0.98 +1.86% With a day low of 52.29 and a total volume of 6,135,433.

CTSH Recent Posts: http://investorshangout.com/Cognizant-Technol...TSH-53834/

CTSH Cognizant Technology Solutions Recent Headline News

Company News for November 06, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 9:10AM CST
Companies in the News are: ACT,CTSH,COV,TW
ACT: 245.91 (-4.47), COV: 92.08 (-0.52), CTSH: 53.62 (+0.98), TW: 114.66 (+1.16)

Cognizant Technology
at Investor's Business Daily - Wed Nov 05, 5:41PM CST
Cognizant Technology (CTSH) Q3 EPS fell 9.4% to 58 cents, missing estimates by a penny. Revenue jumped 11.9% to $2.581 bil, passing expectations for $2.567 bil. The IT services provider sees full-year EPS of at least $2.57, above projections for...
CTSH: 53.62 (+0.98)

India In Focus: Cognizant Breaks Out, Tata Bases
at Investor's Business Daily - Wed Nov 05, 4:42PM CST
Healthy third-quarter results sent Cognizant Technologies (CTSH) up more than 8% Wednesday and placed investor attention on a number of India-related stocks. Cognizant, which began as the Indian IT arm of Dunn & Bradstreet, is a world citizen....
F: 14.17 (-0.02), IBN: 58.01 (-0.82), HDB: 51.84 (-1.05), GM: 31.59 (+0.22), FCAU: 10.94 (-0.04), CTSH: 53.62 (+0.98), TTM: 46.54 (-1.01)

Cognizant Has Solid Quarter, Bullish on Health Care, IT Spending
at The Street - Wed Nov 05, 3:59PM CST
Cognizant Technology Solutions came in with solid third-quarter earnings and provided favorable guidance for the fourth quarter and fiscal year 2014.
IBM: 162.07 (+0.61), INFY: 68.00 (+0.42), CTSH: 53.62 (+0.98)

Cognizant Technology Solutions Rises 8.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Nov 05, 3:55PM CST
Cognizant Technology Solutions (NASDAQ:CTSH) traded in a range yesterday that spanned from a low of $50.45 to a high of $52.60. Yesterday, the shares gained 8.1%, which took the trading range above the 3-day high of $49.46 on volume of 10.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CTSH: 53.62 (+0.98)

Cognizant Tech Solutions (CTSH) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Wed Nov 05, 2:38PM CST
The following Cognizant Tech Solutions (CTSH) conference call took place on November 5, 2014, 08:00 AM ET. This is a transcript of that earnings call:
CTSH: 53.62 (+0.98)

Cognizant CFO Karen McLaughlin Says Health Care, the Cloud Are Key to Growth
at The Street - Wed Nov 05, 12:10PM CST
Cognizant beat predictions on earnings, but now faces the challenge of becoming a major player in health care IT.
MCK: 199.32 (-3.34), WDAY: 94.56 (-0.43), CTSH: 53.62 (+0.98), HNT: 47.01 (-1.08), CERN: 63.01 (-0.87), CRM: 63.97 (+0.88)

Cognizant Technology Beats on Q3 Earnings and Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:00PM CST
Cognizant Technology Solutions Corp. (CTSH), reported third-quarter 2014 earnings of 66 cents per share, which beat the Zacks Consensus Estimate.
WIT: 12.55 (+0.10), INFY: 68.00 (+0.42), CTSH: 53.62 (+0.98), ACN: 83.48 (+0.24)

Cognizant (CTSH) Stock Soars on Increased Fourth Quarter Earnings Outlook
at The Street - Wed Nov 05, 11:14AM CST
Cognizant (CTSH) stock is rising after the company raised its fourth quarter earnings and revenue guidance, following its better than expected third quarter earnings this morning.
CTSH: 53.62 (+0.98)

Today's Unusual Social Activity Stock: Cognizant Technology Solutions (CTSH)
at The Street - Wed Nov 05, 8:59AM CST
Trade-Ideas LLC identified Cognizant Technology Solutions (CTSH) as an unusual social activity candidate
CTSH: 53.62 (+0.98)

Cognizant beats Street 3Q forecasts
Automated Insights - Wed Nov 05, 5:18AM CST
TEANECK, N.J. (AP) _ Cognizant Technology Solutions Corp. (CTSH) on Wednesday reported net income of $355.6 million in its third quarter.
CTSH: 53.62 (+0.98)

Cognizant Announces Third Quarter 2014 Results
PR Newswire - Wed Nov 05, 5:00AM CST
Cognizant Technology Solutions Corporation (NASDAQ: CTSH), a leading provider of information technology, consulting, and business process outsourcing services, today announced its third quarter 2014 financial results.
CTSH: 53.62 (+0.98)

Health Net Q3 Earnings Miss By a Penny, Guidance Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:00PM CST
Health Net's (HNT) third-quarter 2014 operating income of 72 cents per share missed the Zacks Consensus Estimate by a penny and decreased 13% year over year due to higher expenses.
CTSH: 53.62 (+0.98), HNT: 47.01 (-1.08), MOH: 48.75 (+0.15), WLP: 124.15 (-3.65)

Cognizant (Nasdaq: CTSH) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Tue Nov 04, 9:00AM CST
What:
QQQ: 101.60 (-0.09), NDAQ: 43.88 (-0.02), CTSH: 53.62 (+0.98)

Can Cognizant (CTSH) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 5:12PM CST
Cognizant Technology Solutions Corp (CTSH) is set to report third quarter 2014 results on Nov 5.
ACT: 245.91 (-4.47), DIS: 90.00 (-2.00), ACN: 83.48 (+0.24), CTSH: 53.62 (+0.98)

Insider Trading Alert - CTSH, OMC And LLY Traded By Insiders
at The Street - Mon Nov 03, 9:15AM CST
Stocks with insider trader activity include CTSH, OMC and LLY
OMC: 72.71 (-0.10), LLY: 66.60 (-0.36), CTSH: 53.62 (+0.98)

Sapient To Be Acquired By Publicis; Digital Ad Push
at Investor's Business Daily - Mon Nov 03, 9:06AM CST
France-based Publicis Groupe late Sunday announced it's agreed to acquire Sapient for $3.7 billion in a move to speed up its push into digital advertising. Sapient stockholders will receive $25 in cash per share, a 44% premium to Sapient's close on...
INFY: 68.00 (+0.42), ACN: 83.48 (+0.24), CTSH: 53.62 (+0.98)

Health Net Reports Third Quarter 2014 GAAP Net Loss of $8.9 Million, or a Loss of $0.11 Per Share
Business Wire - Mon Nov 03, 7:30AM CST
--Health Plan Enrollment Climbs 24.7 Percent Year-over-Year, and Surpasses 3 Million Members, Driven by Continued Medicaid Growth from Expansion and Commercial Growth from Individual Exchanges
CTSH: 53.62 (+0.98), HNT: 47.01 (-1.08)

Health Net Enters into Seven-Year Master Services Agreement with Cognizant
Business Wire - Mon Nov 03, 7:20AM CST
Health Net, Inc. (NYSE:HNT) today announced that it has entered into a master services agreement with Cognizant Healthcare Services, LLC, an indirect, wholly owned subsidiary of Cognizant Technology Solutions Corporation (NASDAQ:CTSH) (Cognizant), a leading provider of information technology, consulting and business process services.
CTSH: 53.62 (+0.98), HNT: 47.01 (-1.08)

Cognizant Technology Solutions (CTSH) Stock Research Links

CTSH Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 313

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 193

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 128

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 130

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 224

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 332

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 134

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 541

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 161

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading

Top 5 Most Recently Viewed Articles

Phreesia Announces Q3 Fiscal Year 2025 Financial Results

Updated Category News Views 71

Phreesia to Release Fiscal Q3 2025 Results Soon Phreesia, Inc. (NYSE: PHR) has great news for its stakeholders! The company revealed plans to announce its financial results for the third quarter of fiscal year 2025 right after market closing on a Monday in December. During this quarter, the firm experienced substantial growth and is eager to share the details with the...

Continue Reading
Innovative Water Bowl Design Enhances Pet Hydration Experience

Updated Category News Views 374

Revolutionary Pet Water Bowl Crafted for Optimal Hydration Every pet owner knows the importance of keeping their furry friends hydrated, especially during hot days. A new invention promises to enhance the experience for pets and their owners alike. This innovative water bowl, known as the THERMA DRINK, is designed with features that cater directly to pet needs. The idea...

Continue Reading
HPH's Leadership Changes Signify Strategic Direction Ahead

Updated Category News Views 177

Leadership Transitions at HPH Highest Performances Holdings Inc. (NASDAQ: HPH) has recently seen a notable change in its Board of Directors. The company announced that Mr. Peh Chin Hua's tenure as Director has come to an end, effective immediately. This decision is part of a broader strategy aimed at strengthening the Board's overall composition and capabilities. Current...

Continue Reading
Apranga Group Reports Growth in Retail Turnover for 2025

Updated Category News Views 132

Apranga Group Retail Performance Overview for 2025 Apranga Group, a major player in the retail sector, has announced its impressive financial performance for the first six months of 2025, demonstrating notable growth compared to the prior year. The company's retail turnover reached a commendable EUR 166.1 million, reflecting a 2.8% increase from the same period in 2024....

Continue Reading
IMUNON Unveils Promising New Vaccine Data for COVID-19

Updated Category News Views 154

New Vaccine Insights from IMUNON's Phase 1 Clinical Trial The innovative PlaCCine technology platform developed by IMUNON, Inc. (NASDAQ: IMNN) promises remarkable durability and advantages over traditional mRNA vaccines, particularly in the struggle against COVID-19. Robust Results from IMNN-101 Vaccine Trials In an encouraging announcement, IMUNON shared pivotal data...

Continue Reading